Takeda Pharmaceutical Company Limited

Cardurion Pharmaceuticals, LLC

Terufumi Takagi

Masanori Okaniwa

Atsushi Hasuoka

Yusuke Sasaki

Akito Shibuya

Zenyu Shiokawa

Yusuke Tominari

Masato Yoshida

Masaaki Hirose

Junya Shirai

Shinichi Imamura

Xiaolun Wang

Kazuaki Takami

Tomohiro Okawa

Keiko Kakegawa

Masahiro Kajino

Nicholas Scorah

Takaharu Hirayama

Haruyuki Nishida

Minoru Yoshida

John S Tyhonas

Phong H Vu

Mark Sabat

Yasufumi Miyamoto

Yasuhiro Hirata

Joanne Miura

Rei Okamoto

Yoichi Nishikawa

Yuta Tanaka

Haixia Wang

Nobuyuki Matsunaga

Tony Gibson

Yoshito Terao

Takafumi Yukawa

Lily Kwok

Mallareddy Komandla

Moriteru Asano

Naoki Iwamura

Takeshi Yoshikawa

Takashi Nakahata

Hiroki Takahagi

Paul Tanis

Xin Liu

Takuto Kojima

Hiroshi Banno

Yasutomi Asano

Naoki Tarui

Osamu Kurasawa

Douglas Robert Cary

Jun Fujimoto

Takashi Ichikawa

Yoko Hayashi

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification,or a salt thereof.

Substituted amines for treating cardiac diseases

Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Heterocyclic amide compound

Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.

Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Heterocyclic compound

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

A proton pump inhibitor containing a compound represented by the formula (I) wherein X and Y are the same or different and each is a bond or a spacer having 1 to 20 carbon atoms in the main chain, Ris an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, R, Rand Rare the same or different and each is a hydrogen atom, an optionally substituted hydrocarbon group, an optionally substituted thienyl group, an optionally substituted benzo[b]thienyl group, an optionally substituted furyl group, an optionally substituted pyridyl group, an optionally substituted pyrazolyl group, an optionally substituted pyrimidinyl group, an acyl group, a halogen atom, a cyano group or a nitro group, Rand Rare the same or different and each is a hydrogen atom or an optionally substituted hydrocarbon group, which has a superior proton pump action and shows an antiulcer activity and the like after conversion to a proton pump inhibitor in the body, or a salt thereof, or a prodrug thereof is provided.

Proton pump inhibitors

The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

The present invention provides a compound having a superior acid secretion inhibitory action, an antiulcer activity and the like. A proton pump inhibitor containing a compound represented by the formula (I) wherein ring A is a saturated or unsaturated 5- or 6-membered ring group optionally having, as a ring-constituting atom besides carbon atom, 1 to 4 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, ring-constituting atoms Xand Xare each a carbon atom or a nitrogen atom, a ring-constituting atom Xis a carbon atom, a nitrogen atom, an oxygen atom or a sulfur atom, Ris an optionally substituted aryl group or an optionally substituted heteroaryl group, Ris an optionally substituted alkyl group, an optionally substituted aryl group or an optionally substituted heteroaryl group, Ris an aminomethyl group optionally substituted by 1 or 2 lower alkyl groups, which is a substituent on a ring-constituting atom other than X, Xand X, and ring A optionally further has substituent(s) selected from a lower alkyl group, a halogen atom, a cyano group and an oxo group, or a salt thereof or a prodrug thereof.

Aryl- or heteroaryl-sulfonyl compounds as acid secretion inhibitors

Provided is a fused heterocycle derivative showing a strong Raf inhibitory activity. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

Heterocyclic compound and use thereof

The present invention provides a heterocyclic compound having a strong Raf inhibitory activity, which is represented by the following formula wherein each substituent is as defined in the present specification, or a salt thereof.

Benzothiazole compounds useful for Raf inhibition

The present invention provides an aryl- or heteroaryl compound represented by the formula (Ia) or (Ib) wherein each symbol is as defined in the specification, or a salt thereof, or a pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier. The compound has superior acid secretion inhibitory action, an antiulcer activity and the like.

Aryl-or heteroaryl-sulfonyl compounds as acid secretion inhibitors

Growing community of inventors

Kanagawa, Japan

Terufumi Takagi